MPD: Measures involving health assessment

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Boon1:21	Boon1	health assessment	influenza A (H5N1) virus	survival (days to death, max 30) [d] survival 46921 dosage group: low medium high	inbred	23	f	6-9wks	N=11	2011

Boon1:31	Boon1	health assessment	influenza A (H5N1) virus	susceptibility to viral infection (0=susceptible, 1=resistant) [designation] resistance 46931 dosage group: low medium high	inbred	23	f	6-9wks	N=11	2011

Bopp1:1	Bopp1	health assessment	Plasmodium berghei	survival, post-infection [d] survival 36401	inbred	31	both	8-12wks	N=4	2010

Bopp1:2	Bopp1	health assessment	Plasmodium berghei	terminal body temperature, post-infection [°C] body_temp 36402	inbred	31	both	8-12wks	N=4	2010

Bopp1:3	Bopp1	health assessment	Plasmodium berghei	percentage of parasite-infected erythrocytes in blood [%] parasitemia 36403	inbred	31	both	8-12wks	N=4	2010

Bopp1:4	Bopp1	health assessment	Plasmodium berghei	percentage of parasites in brain relative to all organs tested [%] luciferase_brain 36404	inbred	28	both	8-12wks	N=2	2010

Bopp1:5	Bopp1	health assessment	Plasmodium berghei	percentage of parasites in spleen relative to all organs tested [%] luciferase_spleen 36405	inbred	28	both	8-12wks	N=2	2010

Bopp1:6	Bopp1	health assessment	Plasmodium berghei	percentage of parasites in lungs relative to all organs tested [%] luciferase_lungs 36406	inbred	28	both	8-12wks	N=2	2010

Bopp1:7	Bopp1	health assessment	Plasmodium berghei	percentage of parasites in liver relative to all organs tested [%] luciferase_liver 36407	inbred	28	both	8-12wks	N=2	2010

Brinkmeyer1:17	Brinkmeyer1	health assessment	Theiler's murine encephalomyelitis virus	clinical score (0=normal, 6=moribund), post infection [score] clin_score 64417 day 0 day 2 day 4 day 6 day 8 day 12 day 18 day 24 day 29 day 34 (6 more)...	CC	5	both	4wks	N=5	2017

Clemens1:1	Clemens1	health assessment	ultraviolet light	UV-induced immunosuppression of contact hypersensitivity [%] suppression 10601	QTL population		both	9-30wks	N=67	2000

Cowell1:4	Cowell1	health assessment	Staphylococcus aureus	median survival time, max time 104h [h] median_survival 49004	inbred	13	f	8wks	N=11	2012

Cowell1:5	Cowell1	health assessment	Staphylococcus aureus	percent survival, max time 104h [%] pct_survival 49005	inbred	13	f	8wks	N=11	2012

Davidson1:1	Davidson1	health assessment	(none)	0=exencephaly, 1=normal [score] Exencephaly 19201	QTL population		both	embryo	N=94	2007

Davidson1:2	Davidson1	health assessment	(none)	1=exencephaly, 0=normal [score] Exen2 19202	QTL population		both	embryo	N=94	2007

Farmer1:27	Farmer1	health assessment	(none)	diarrhea grade [score] Diarrhea 11327	QTL population		both	6wks	N=206	2001

Ferris1:3	Ferris1	health assessment	influenza A (H1N1) virus	clinical score, day 4 post-infection (score 0-4) [score] clinical_score 47603	CC pre w/par	161	f	8-16wks	N=1	2012

Ferris1:5	Ferris1	health assessment	influenza A (H1N1) virus	susceptibility to viral infection index (0=susceptible; 1= resistant) [score] susceptibility_index 47605	CC pre w/par	161	f	8-16wks	N=1	2012

Graham1:15	Graham1	health assessment	West Nile virus	clinical score (0=healthy, 1=lethargic, 2=altered gait, 3=no movement, 4=moribund), post infection [score] clin_score 63315 day 0 day 3 day 6 day 8 day 9 day 10 day 11 day 12 day 13 day 14 (4 more)...	CC RIX	5	m	8-10wks	N=12	2015

Gros2:2	Gros2	health assessment	Plasmodium chabaudi	percent survival post-infection (max=21d) [%] survival 49302	inbred	25	both	8-10wks	N=5	2012

Gros2:3	Gros2	health assessment	Plasmodium chabaudi	response to infection (0=susceptible, 0.5=intermediate, 1=resistant) [designation] resistance 49303	inbred	25	both	8-10wks	N=5	2012

Haston1:1	Haston1	health assessment	radiation	number of days in the absence of respiratory distress [d] survival 48801	inbred	26	both	15-36wks	N=7	2012

Leiter2:1	Leiter2	health assessment	(none)	age of diabetes onset (dash = no diabetes) [wks] Onset 24001	QTL population		f	14-40wks	N=310	2009

Leiter2:2	Leiter2	health assessment	(none)	1 = diabetes, 0 = no diabetes [score] DB1_0 24002	QTL population		f	14-40wks	N=310	2009

Sandell1:1	Sandell1	health assessment	(none)	ear cartilage wound healing 30d post-injury [mm] ear 49801	LGXSM w/par	13	both	10wks	N=7	2012

Schauwecker1:1	Schauwecker1	health assessment	pilocarpine	pilocarpine dose required to induce status epilepticus, mg/kg body weight [mg/kg] ED100 47701	inbred	8	m	8-10wks	N=4	2012

Schauwecker1:2	Schauwecker1	health assessment	pilocarpine	latency to onset of stage 4 status epilepticus seizures [min] latency 47702	inbred	8	m	8-10wks	N=4	2012

Schauwecker1:3	Schauwecker1	health assessment	pilocarpine	duration of stage 4 status epilepticus seizures [min] duration 47703	inbred	8	m	8-10wks	N=4	2012

Schauwecker1:4	Schauwecker1	health assessment	pilocarpine	status epilepticus seizure mortality (0=died; 1=survived) [designation] survival 47704	inbred	11	m	8-10wks	N=18	2012

Schughart1:5	Schughart1	health assessment	influenza A (H1N1) virus	susceptibility to viral infection (0=susceptible; 1=resistant) [designation] susceptibility 39305	inbred	9	both	10-12wks	N=11	2009

Schughart2:6	Schughart2	health assessment	influenza A (H1N1) virus	survival, post-infection [d] survival_days 49606	BXD w/par	56	f	9-18wks	N=6	2012

Schughart2:7	Schughart2	health assessment	influenza A (H1N1) virus	susceptibility to viral infection (0=susceptible; 1=resistant) [designation] susceptibility 49607	BXD w/par	56	f	9-18wks	N=6	2012

Schughart3:81	Schughart3	health assessment	influenza A (H3N2) virus	survival, post-infection [d] day_survival 57181 10 FFU group 2000 FFU group 200000 FFU group	inbred w/CC8	8	both	7-13wks	N=11	2013

Schughart3:91	Schughart3	health assessment	influenza A (H3N2) virus	susceptibility to viral infection (0=resistant, 1=susceptible), mortality rate [score] status_day_survival 57191 10 FFU group 2000 FFU group 200000 FFU group	inbred w/CC8	8	both	7-13wks	N=11	2013

Boon1

health assessment

influenza A (H5N1) virus

survival (days to death, max 30) [d] survival 46921 dosage group: low medium high

inbred

23

f

6-9wks

N=11

2011

Boon1

health assessment

influenza A (H5N1) virus

susceptibility to viral infection (0=susceptible, 1=resistant) [designation] resistance 46931 dosage group: low medium high

inbred

23

f

6-9wks

N=11

2011

Bopp1

health assessment

Plasmodium berghei

survival, post-infection [d] survival 36401

inbred

31

both

8-12wks

N=4

2010

Bopp1

health assessment

Plasmodium berghei

terminal body temperature, post-infection [°C] body_temp 36402

inbred

31

both

8-12wks

N=4

2010

Bopp1

health assessment

Plasmodium berghei

percentage of parasite-infected erythrocytes in blood [%] parasitemia 36403

inbred

31

both

8-12wks

N=4

2010

Bopp1

health assessment

Plasmodium berghei

percentage of parasites in brain relative to all organs tested [%] luciferase_brain 36404

inbred

28

both

8-12wks

N=2

2010

Bopp1

health assessment

Plasmodium berghei

percentage of parasites in spleen relative to all organs tested [%] luciferase_spleen 36405

inbred

28

both

8-12wks

N=2

2010

Bopp1

health assessment

Plasmodium berghei

percentage of parasites in lungs relative to all organs tested [%] luciferase_lungs 36406

inbred

28

both

8-12wks

N=2

2010

Bopp1

health assessment

Plasmodium berghei

percentage of parasites in liver relative to all organs tested [%] luciferase_liver 36407

inbred

28

both

8-12wks

N=2

2010

Brinkmeyer1

health assessment

Theiler's murine encephalomyelitis virus

clinical score (0=normal, 6=moribund), post infection [score] clin_score 64417 day 0 day 2 day 4 day 6 day 8 day 12 day 18 day 24 day 29 day 34 (6 more)...

CC

5

both

4wks

N=5

2017

Clemens1

health assessment

ultraviolet light

UV-induced immunosuppression of contact hypersensitivity [%] suppression 10601

QTL population

both

9-30wks

N=67

2000

Cowell1

health assessment

Staphylococcus aureus

median survival time, max time 104h [h] median_survival 49004

inbred

13

f

8wks

N=11

2012

Cowell1

health assessment

Staphylococcus aureus

percent survival, max time 104h [%] pct_survival 49005

inbred

13

f

8wks

N=11

2012

Davidson1

health assessment

(none)

0=exencephaly, 1=normal [score] Exencephaly 19201

QTL population

both

embryo

N=94

2007

Davidson1

health assessment

(none)

1=exencephaly, 0=normal [score] Exen2 19202

QTL population

both

embryo

N=94

2007

Farmer1

health assessment

(none)

diarrhea grade [score] Diarrhea 11327

QTL population

both

6wks

N=206

2001

Ferris1

health assessment

influenza A (H1N1) virus

clinical score, day 4 post-infection (score 0-4) [score] clinical_score 47603

CC pre w/par

161

f

8-16wks

N=1

2012

Ferris1

health assessment

influenza A (H1N1) virus

susceptibility to viral infection index (0=susceptible; 1= resistant) [score] susceptibility_index 47605

CC pre w/par

161

f

8-16wks

N=1

2012

Graham1

health assessment

West Nile virus

clinical score (0=healthy, 1=lethargic, 2=altered gait, 3=no movement, 4=moribund), post infection [score] clin_score 63315 day 0 day 3 day 6 day 8 day 9 day 10 day 11 day 12 day 13 day 14 (4 more)...

CC RIX

5

m

8-10wks

N=12

2015

Gros2

health assessment

Plasmodium chabaudi

percent survival post-infection (max=21d) [%] survival 49302

inbred

25

both

8-10wks

N=5

2012

Gros2

health assessment

Plasmodium chabaudi

response to infection (0=susceptible, 0.5=intermediate, 1=resistant) [designation] resistance 49303

inbred

25

both

8-10wks

N=5

2012

Haston1

health assessment

radiation

number of days in the absence of respiratory distress [d] survival 48801

inbred

26

both

15-36wks

N=7

2012

Leiter2

health assessment

(none)

age of diabetes onset (dash = no diabetes) [wks] Onset 24001

QTL population

f

14-40wks

N=310

2009

Leiter2

health assessment

(none)

1 = diabetes, 0 = no diabetes [score] DB1_0 24002

QTL population

f

14-40wks

N=310

2009

Sandell1

health assessment

(none)

ear cartilage wound healing 30d post-injury [mm] ear 49801

LGXSM w/par

13

both

10wks

N=7

2012

Schauwecker1

health assessment

pilocarpine

pilocarpine dose required to induce status epilepticus, mg/kg body weight [mg/kg] ED100 47701

inbred

8

m

8-10wks

N=4

2012

Schauwecker1

health assessment

pilocarpine

latency to onset of stage 4 status epilepticus seizures [min] latency 47702

inbred

8

m

8-10wks

N=4

2012

Schauwecker1

health assessment

pilocarpine

duration of stage 4 status epilepticus seizures [min] duration 47703

inbred

8

m

8-10wks

N=4

2012

Schauwecker1

health assessment

pilocarpine

status epilepticus seizure mortality (0=died; 1=survived) [designation] survival 47704

inbred

11

m

8-10wks

N=18

2012

Schughart1

health assessment

influenza A (H1N1) virus

susceptibility to viral infection (0=susceptible; 1=resistant) [designation] susceptibility 39305

inbred

9

both

10-12wks

N=11

2009

Schughart2

health assessment

influenza A (H1N1) virus

survival, post-infection [d] survival_days 49606

BXD w/par

56

f

9-18wks

N=6

2012

Schughart2

health assessment

influenza A (H1N1) virus

susceptibility to viral infection (0=susceptible; 1=resistant) [designation] susceptibility 49607

BXD w/par

56

f

9-18wks

N=6

2012

Schughart3

health assessment

influenza A (H3N2) virus

survival, post-infection [d] day_survival 57181 10 FFU group 2000 FFU group 200000 FFU group

inbred w/CC8

8

both

7-13wks

N=11

2013

Schughart3

health assessment

influenza A (H3N2) virus

susceptibility to viral infection (0=resistant, 1=susceptible), mortality rate [score] status_day_survival 57191 10 FFU group 2000 FFU group 200000 FFU group

inbred w/CC8

8

both

7-13wks

N=11

2013

Filter Table Results